Halt on TSCA ‘non 5(e) Snurs’ raises industry concerns
Consent orders causing delays, stifling innovation, say stakeholders
The US EPA’s apparent policy to stop using ‘non-5(e) Snurs’ under the new TSCA is delaying products from coming to market and stifling innovation of safer alternatives, according to some chemical manufacturers and industry consultants.
At the American Chemistry Council’s (ACC) recent GlobalChem conference in Washington, DC, concerns were raised over growing pains in the EPA’s new chemicals programme since passage of the Lautenberg Act.
Several industry representatives pointed to the agency’s altered approach on consent orders and significant new use rules (Snurs) as a source of this anxiety.
Under the reformed TSCA, the new chemicals review process has slowed, and the percentage of substances subject to consent orders has risen sharply. And with these changes, it appears that the EPA has also discontinued its use of so-called non-5(e) Snurs to manage potentially concerning uses outside of those enumerated in a pre-manufacture notice (PMN).
Speaking at an SME session during GlobalChem, attorney Jamie Conrad said that "the EPA is saying unofficially that they can’t do [non-5(e) Snurs] anymore because of the new law."
"I have yet to figure out what provision of the new law prevents them from doing it, and they haven't ever said that officially so that we can have a conversation," he added.
The EPA did not respond to a Chemical Watch request for comment by publishing time. But the agency's website indicates that "a small subset of PMNs that previously would have been 'dropped' from review and for which a non-section 5(e) Snur would have been issued ... will now be subject to [5(e)] orders."
'Life has changed'
Speaking at the event, Marcia Levinson, regulatory affairs specialist at chemicals firm Covestro, said that “life has changed for industry” as far as new chemicals are concerned.
The advent of the EPA no longer using non-5(e) Snurs means that now new substance manufacturers must frequently enter into a consent order for "something that they did not even foresee in their PMN application", she said.
And while the order is being written, the manufacturer must wait beyond the 90-day PMN review period before their new substance can go to market – a process she says takes a minimum of 60 days. The resulting consent order may also contain testing requirements for foreseeable uses.
"This definitely has an impact on our innovative spirit," she said.
Further, she said that it is more challenging to sell a regulated product than a non-regulated one.
"The perception is that a regulated chemical is much more hazardous than a non-regulated chemical," said Ms Levison. "Therefore we've got a discrepancy in terms of the perception of the impact of this regulation."
Even if companies are able to work with customers to explain that this is simply the new way of doing business, there is still the added burden of managing a regulated chemical, such as recordkeeping requirements, export notifications, lower chemical data reporting (CDR) rule reporting thresholds, or changes to existing hazcom practices.
For these reasons, she said, "it's hard to get customers to go toward these new chemicals."
Lisa Marie Nespoli, also of Covestro, agreed: "We're creating safer models that are more sustainable, and nobody wants to buy them because they have the recordkeeping [requirements]."
"That is our biggest concern for our innovation pipeline – we are creating things that are better, this is what everybody wants – but yet we can't get them through, and I don't know how we fix that."
Changes to consent orders, Snurs under new TSCA
TSCA section 5(e) orders – including consent orders – are only binding to the original pre-manufacture notice (PMN) submitter. As a consequence, the EPA typically promulgates a significant new use rule (Snur) that mimics the 5(e) order so that all subsequent manufacturers and processors of the substance will be bound to the same requirements.
The agency has continued the practice of these so-called 5(e) Snurs under the new law.
This does not appear to be the case, however, for non-5(e) Snurs, or Snurs issued in the absence of a consent order. Before TSCA reform, the EPA would often use these when it determined that the specific conditions of use and precautions described in a PMN would not pose an unreasonable risk, but for which additional uses may be concerning.
In these cases, the agency would ‘drop’ the PMN – that is, allow the substance to come to market – and subsequently issue a non-5(e) Snur that defined additional uses or conditions that may be problematic. Any future engagement in such activities by a manufacturer or processor would thereby require notifying the agency before doing so.
But under the new TSCA, the agency may no longer drop a PMN; it must instead make an affirmative finding that the substance is not likely to present an unreasonable risk. And in order to meet this bar, it has apparently interpreted the statute as requiring it to impose a consent order on the original submitter to block potentially foreseen uses, even if they are not named in the PMN. The use of non-5(e) Snurs has correspondingly dropped off.
This change has resulted in real consequences for the PMN submitter. Not only is that company likely to experience delays in coming to market while a consent order is negotiated, but it also may face additional testing requirements for uses it has not indicated an intent to pursue.
Previously, this testing burden had fallen to those manufacturers or processors submitting significant new use notifications (Snuns) for any potentially concerning uses identified in the Snur.
2026-10-13
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
DKSH Expands Partnership with Assessa to Distribute Botanical Ingredients Across China
-
EU Low-Value Parcel Rules Could Disrupt Chemical Sample Flows
-
EU May Build Industry-Level Trade Barriers Against Chinese Chemicals
-
China’s TiO₂ Industry Launches Sixth Price Hike Wave as More Than 20 Producers Follow
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
-
APVMA Suspends Dimethoate Use on Select Berries Amid Updated Exposure Assessment
Recommend Reading
-
Wanhua USA Reaches $7.75 Million Settlement in MDI/TDI Antitrust Lawsuit
-
U.S. Fighter Jet Strikes Commercial Cargo Ship in Gulf of Oman, Disabling Propulsion
-
Mitsubishi Chemical Exits 105,000-Tonne Taiwan MMA Business as China Capacity Reshapes Asian Market
-
Shandong’s Export Growth Is 2.8%; This Category Is 19%: Shandong Has a Chokehold on the Upstream of Global Manufacturing
-
Continental Tires Out, Franchise Power In: Continental Group Spins Off French Retail Arm to ASC in Strategic Pivot
-
In August, the domestic propylene oxide market showed an upward trend in price levels
-
FDA Lifts Administrative Stay, Restoring Red No. 3 Ban Timeline for Food and Ingested Drugs
-
This Week's Pure Benzene Market Prices Rise in China (8.31-9.4)
-
This Week's Styrene Market Rises Sharply (8.31-9.4) in China
-
Polyethylene Rises and Falls, Operating with High-Level Fluctuations